Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$82.88K$82.88Kderived+508.8% vs Q4 2021 Net Income-$1.16M-$1.16MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,185,837N/M Operating Cash Flowderived-$449,576N/M Margins · derivedOperating margin-1430.8%+8360.1 pt vs Q4 2021
Net margin-1403.3%+7422.4 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end